ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

The Vitamin D Debate in CKD and SHPT: How High Should We Aim?

November 08, 2019 | 12:45 PM - 01:45 PM

Location: Independence Ballroom, Marriott Marquis

Session Description

Vitamin D therapy is commonly prescribed for patients with CKD and secondary hyperparathyroidism (SHPT). However, despite decades of vitamin D use, there remains a lack of consensus in important areas of clinical practice regarding therapeutic goals for 25-hydroxyvitamin D in patients with CKD with SHPT and vitamin D insufficiency. Using current therapies and emerging alternatives, speakers debate the appropriate target level for 25-hydroxyvitamin D for these patients.

Support is provided by an educational grant from OPKO Pharmaceuticals, LLC.

Learning Objective(s)

  • Describe the current clinical practice guideline target for 25-hydroxyvitamin D in healthy people as well as patients with CKD
  • Debate what level of 25-hydroxyvitamin D should be considered optimal for patients with CKD and ESKD

Learning Pathway(s)

  • Bone and Mineral Metabolism

Moderator

  • Michal L. Melamed, MD

Presentations

  • Introduction
    12:45 PM - 12:55 PM
    Michal L. Melamed, MD 
  • Higher 25-Hydroxyvitamin D Targets Are Better for Patients with Kidney Disease
    12:55 PM - 01:15 PM
    James B. Wetmore, MD, MS
  • Lower 25-Hydroxyvitamin D Targets Are Better for Patients with Kidney Disease
    01:15 PM - 01:35 PM
    Julia J. Scialla, MD, FASN 
  • Questions and Answers
    01:35 PM - 01:45 PM